

NCIC CLINICAL TRIALS GROUP

GENITO-URINARY

DISEASE SITE COMMITTEE MEETING

AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Friday, October 17, 2003 - 9:00 a.m. - 3:30 p.m.
Room: Rosetti

Chair: Dr. Martin Gleave

Welcome, Minutes and Chair's report

Dr. M. Gleave

CTSU UPDATE

CURRENT PHASE III PROSTATE TRIALS

PR.3

PR.7

PR.8

PR.10 / ACOSOG

BL.7 / EORTC 30987

BL 8 / EORTC 30994

PRP.1

Dr. P. Warde
Drs. J. Crook/ L. Klotz
Dr. B. Donnelly
Drs. J. Crook/ N. Fleshner
Drs. M. Moore/ E. Winquist
Drs. A. Aprikian/ L Wood
Dr. N. Fleshner

CLOSED TRIALS

PR.5 Final Results

Dr. H. Lukka

TRIALS APPROVED/PENDING ACTIVATION

PR.9 / RTOG (RTOG P0011)

BL.10 (SWOG P53)

Dr. R. Choo

Dr. L. Klotz

REPORT FROM DOGS

Advanced Prostate Cancer

Localized Prostate Cancer

Superficial Bladder

Advanced Bladder

Kidney

Testes

Dr. K. Chi
Dr. L. Klotz
Dr. L. Lacombe
Dr. E. Winquist
Dr. S. Tanguay
Dr. P. Warde

IND TRIALS

IND.143: MG 98 Renal Cell Phase II

IND.153: OGX-011 Prostate Ca Phase I

IND.154: OGX-011 + Taxotere Phase I

IND.161: Triapine Phase II

Dr. E. Winquist

Dr. Kim Chi

Dr. Kim Chi

Dr. J. Knox

TRIALS UNDER DEVELOPMENT

Salvage RT+ AA +/- bisphosphonates

NHT Taxotere prior to XRT

Surveillance with delayed Intervention for early prostate cancer

Dr. R. Choo
Dr. M. McKenzie
Dr. R. Choo/Dr. L. Klotz

continued . . .

OTHER

ALL

TRIALS UNDER CONSIDERATION

EORTC Intermediate Risk Testes Trial Update

Dr. E. Winquist / Dr. P. Warde

CTSU TRIALS ENDORSED BY NCIC CTG

REC.1/CALGB 90206 A Phase III trial of interferon alpha (IFNA) or IFNA plus bevacizumab in advanced renal carcinoma

AVAILABLE FOR ENDORSEMENT: ACTIVE PROTOCOLS

E1899: A phase III randomized trial for evaluating second line hormonal therapy (ketoconazole/hydrocortisone) versus docetaxel/estramustine combination chemotherapy on progression free survival in asymptomatic patients with a rising PSA after hormonal therapy for prostate cancer

MDA 3410: A prospective randomized phase III trial comparing consolidation therapy with or without strontium-89 following induction chemotherapy in androgen-independent prostate cancer

RTOG 0232: Phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma

RTOG 9902: A phase III protocol of androgen suppression (AS) and radiation therapy (RT) vs AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk prostate cancer

RTOG 9910: A phase III trial to evaluate the duration of neoadjuvant total androgen suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer

RTOG P-0014: Phase III randomized study of patients with high-risk, hormone naïve prostate cancer: Androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy

Consideration for endorsement/Protocols in development

CALGB 90104 A randomized phase III study comparing sequential chemotherapy (AG-TP) to cisplatin and gemcitabine as adjuvant treatment after cystectomy for transitional cell carcinoma of the bladder

CALGB 90106 A randomized phase III study of paclitaxel, ifosfamide and cisplatin vs. vinblastine, ifosfamide and cisplatin as second-line therapy for patients with relapsed/resistant germ cell tumors

CALGB 90202 A randomized phase III study of early versus delayed zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone

CALGB 90203 A randomized phase III study of radical prostatectomy alone versus estramustine and docetaxel prior to radical prostatectomy for patients with high-risk localized prostate cancer

continued . . .

REPORT FROM CUOG

CUOG P-01a-NHT/Taxotere
CUOG P-01b-Taxotere 327
Atrasentin trials (PSA only, M+) – CURC
BCG bladder
Antigenics adjuvant RCCa trial
Taxotere + calitriol in HRPC
Genesense + Taxotere in HRPC

Dr. M.Gleave
Dr. I. Tannock
Dr. L. Klotz
Dr. L. Lacombe
Dr. S. Tanguay
Dr. Kim Chi
Dr. Kim Chi

REPORT FROM GLOBAL GU GROUP

Dr. L. Klotz

OTHER BUSINESS

Closed Executive meeting to follow.